<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

WEBINAR SERIES: Unlocking Tomorrow´s Cure for Cancer
Leveraging 3D In Vitro Models for Oncology Drug Discovery

Presented by Dr Rajendra Kumari this webinar will discuss new advances in 3D tumor modelling and how these are contributing to reshaping model choice in drug development. She will review benefits and limitations from available 2D and 3D in vitro tumor models, introduce organoids, and discuss the need for multiple tools and in depth expertise to unravel early stage data and progress successful candidates.

Introducing Our New Mouse I/O RNA-Seq Panel

Explore our new NGS-based murine targeted panel for I/O and TME studies. Learn how to leverage the panel to gain in-depth genomic insight into immune cell populations and the I/O pathways and processes of your murine immunity pharmacology study samples.

Safety and Toxicity Services to Evaluate Immune-Related Adverse Events (irAEs)

Learn how to leverage the novel HuGEMM™ human target knock-in models to study toxicities associated with human-specific immunotherapies. Explore how both the efficacy and toxicity of your immuno-oncology compound can be assessed in the same animal model system to accelerate your drug discovery programs.

NEW WHITE PAPER: Learn When and How to Use Tumor Organoids in Oncology Drug Discovery

Learn how to select the right in vitro platform for each stage of your drug development program based on model features, benefits, and limitations. Explore the optimal applications of tumor organoids, a superior and predictive research system for oncology drug development, and how to best utilize them alongside conventional platforms.

ON DEMAND WEBINAR: Shifting the Paradigm of Cancer Treatment: How Can Optical Imaging Help?

Join Dr Yinfei Yin to explore the benefits of optical imaging in preclinical oncology research with an emphasis on immunotherapy development. Learn how imaging improves the predictive power of preclinical studies, and allows a more efficient and cost-effective translation into the clinic. Key new imaging models for evaluating novel anticancer agents will also be discussed.

Keeping Your Projects Moving During the

COVID-19 Pandemic

Read the update from Dr. Jean-Pierre Wery, CEO on how we're balancing our operations while keeping our staff and facilities safe. Find out more about our current global capacity - with all China sites fully operational, and a Proxy SD system for EU/US affected areas

ON DEMAND WEBINAR: Next Generation Syngeneic Models to Facilitate Immuno-Oncology Research

Join Dr Davy Ouyang to discover the latest cutting edge syngeneic research driving immuno-oncology development. Learn more about deep kinetic profiling, and how immune cell depletion studies are used to explore mediation of immunotherapy response. Engineered and bioluminescent syngeneics will also be discussed, as well as novel I/O platforms for moving beyond standard syngeneic studies.

NEW PUBLICATION: Genomic Analysis of Clinical Chinese ccRCC Samples to Guide Patient Stratification

Explore whole-transcriptomic analysis of tumor and matched normal tissues from Chinese ccRCC patients, to investigate differences in expression profiles across Chinese and Caucasian populations. Discover how genomic analysis of clinical samples has the potential to guide patient stratification.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.


Models of Obesity


CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More


Oncology Databases


Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More


Diabetes Models


Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

March 1, 2021

Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development

Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of tumor-infiltrating lymphocytes (TILs) can help evaluating the efficacy of novel immunotherapy agents.

Read More

March 1, 2021

Profiling of Tumor-Infiltrating Immune Cells in Syngeneic Tumor Models to Support Drug Development

Tumor-Infiltrating Immune Cells: Explore how the identification and quantification of...

Read More

December 18, 2020

Factors to Consider When Selecting a Next Generation Sequencing (NGS) Technology

Explore the main factors you need to consider before choosing and using next generation...

Read More

December 16, 2020

Germ-Free or Antibiotic-Treated Mice? Which Model for Studying the Role of the Gut Microbiota in Preclinical Studies

Explore the differences and similarities of germ-free (GF) and antibiotic-treated mice as models...

Read More

December 3, 2020

The Latest Developments on PARP Inhibitors for Prostate Cancer Treatment

Review the status of PARP inhibitors (PARPi) for prostate cancer treatment, with a focus on...

Read More

November 30, 2020

The Rising Importance of GITR Agonists as Alternative I/O Candidates for Combination Drug Strategies

Explore why glucocorticoid-induced TNFR-related protein (GITR or CD357) agonists are becoming...

Read More

Upcoming Events

Week 1: April 10-15, 2021 | Week 2: May 17-21, 2021

AACR Annual Meeting 2021


April 13, 2021

Organoid Discovery